Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of...
CORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst or Company) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Santhera™s Partner Catalyst Launches AGAMREE® (Vamorolone) in the United States
Catalyst Pharmaceuticals Announces AGAMREE Now Commercially Available
Catalyst to Participate at the Barclays 26th Annual Global Healthcare Conference